NMT Medical dives on Closure I trial failure

June 17, 2010 by MassDevice staff

NMT Medical Inc.'s Closure I trial fails to meet its primary endpoint, sending its stock down nearly 75 percent in late-day trading.

NMTI logo

A clinical trial of NMT Medical Inc.'s (NSDQ:NMTI) flagship StarFlex device failed to meet its primary endpoint, sending the company's stock down 5 percent in late-day trading.

The Boston-based company said its Closure I trial, examining the use of its cardiac implant in treating stroke and transient ischemic attack, failed to meet its primary endpoint of demonstrable superiority to "current best medical therapy for preventing recurrent strokes and TIAs," according to a press release.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.